Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sigma HealthcareASX:SIG +0.34%53 3-1 Month Momentum % is -4.45% as of Aug. 05, 2026. GuruFocus rates ASX:SIG with a GF Score™ of 53/100 and a GF Value™ of A$0.37 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 121 Medical Distribution companies, Sigma Healthcare ranks better than 62.81% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-05), Sigma Healthcare's 3-1 Month Momentum % is -4.45%.
The industry rank for Sigma Healthcare's 3-1 Month Momentum % or its related term are showing as below:
ASX:SIG's 3-1 Month Momentum % is ranked better than 62.81% of 121
companies
in the Medical Distribution industry
Industry Median: -5.68
vs ASX:SIG: -4.45
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Sigma Healthcare 3-1 Month Momentum % Related Terms
ASX:SIG vs MCK, COR, CAH: 3-1 Month Momentum % Comparison
For the Medical Distribution subindustry, Sigma Healthcare's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sigma Healthcare 3-1 Month Momentum % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sigma Healthcare's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Sigma Healthcare's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sigma Healthcare (ASX:SIG) has a 3-1 Month Momentum % of -4.45% as of Aug. 05, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sigma Healthcare and its competitors. According to the industry distribution chart, Sigma Healthcare ranks #45 out of 121 companies in the Medical Distribution industry, placing it in the top 37.2%.
Is Sigma Healthcare's 3-1 Month Momentum % too high?
Sigma Healthcare's current 3-1 Month Momentum % is -4.45%. Based on the distribution chart, Sigma Healthcare ranks #45 out of 121 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sigma Healthcare has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sigma Healthcare's 3-1 Month Momentum % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sigma Healthcare ranks #45 out of 121 companies for 3-1 Month Momentum %. This puts Sigma Healthcare in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Distribution company?
A good 3-1 Month Momentum % depends on the Medical Distribution industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sigma Healthcare and its competitors. Sigma Healthcare's current 3-1 Month Momentum % is -4.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigma Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sigma Healthcare (ASX:SIG) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.37, compared to a current price of A$2.98 — trading 705.4% above its estimated fair value. The current 3-1 Month Momentum % is -4.45%. Sigma Healthcare's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Sigma Healthcare (ASX:SIG), the current 3-1 Month Momentum % is -4.45% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sigma Healthcare (ASX:SIG) Overvalued in 2026?
Based on GuruFocus' analysis, Sigma Healthcare stock appears to be overvalued.
The current stock price of A$2.98 is trading 705.4% above its estimated GF Value™ of A$0.37.
GuruFocus considers Sigma Healthcare to be Significantly Overvalued.
Key valuation signals for ASX:SIG:
3-1 Month Momentum %: -4.45%
GF Value™: A$0.37 vs. price of A$2.98 (705.4% above fair value)
No single metric tells the full story. See the ASX:SIG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sigma Healthcare is Australia's largest retail pharmacy franchisor, most notably owning the Chemist Warehouse brand, which it merged with in 2025. Sigma is also Australia's largest full-line wholesaler to franchised and independent pharmacies and distributes a broad range of pharmacy products, including prescription medicines, over-the-counter products, and front of store, or FOS, products, at low prices. The group also operates in New Zealand, Ireland, China, and Dubai, has a growing private label range, and offers third-party logistics services.
53GF Score
Get the complete analysis for ASX:SIG
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SIG has been successfully added to your 
